Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4122808 | 1.00 | GAA (0.46) | GAAMRGPRX2KDM4ECYP3A4MAPT | |
| SCHEMBL13321578 | 0.87 | OPRM1 (0.39) | GAAMRGPRX2KDM4ECYP3A4MAPT | |
| SCHEMBL13301276 | 0.82 | GAA (0.32) | GAACYP3A4MAPTCYP2D6LMNA | |
| SCHEMBL4114954 | 0.82 | GAA (0.69) | GAAMRGPRX2KDM4ECYP3A4MAPT | |
| SCHEMBL5918336 | 0.82 | GAA (0.69) | GAAMRGPRX2KDM4ECYP3A4MAPT | |
| SCHEMBL14242321 | 0.82 | GAA (0.69) | GAAMRGPRX2KDM4ECYP3A4MAPT | |
| SCHEMBL14242320 | 0.82 | GAA (0.69) | GAAMRGPRX2KDM4ECYP3A4MAPT | |
| SCHEMBL12006853 | 0.82 | GAA (0.69) | GAAMRGPRX2KDM4ECYP3A4MAPT | |
| SCHEMBL5918357 | 0.82 | GAA (0.69) | GAAMRGPRX2KDM4ECYP3A4MAPT | |
| SCHEMBL29225417 | 0.82 | GAA (0.69) | GAAMRGPRX2KDM4ECYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367827-B2 | Process for preparing hydrocodone using a super acid | MALLINCKRODT LLC (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100137598-A1 | Process for Preparing Hydrocodone Using a Super Acid | MALLINCKRODT INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137598-A1 | Process for Preparing Hydrocodone Using a Super Acid | HAAO, CYP7A1, CYP3A5 | GAA 1908/4885MRGPRX2 499/4885KDM4E 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.